Lizhen Yan
Research Subjects
Lizhen Yan has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Hua Cao
Department of Respiratory and Critical Care Medicine, Zibo Municipal Hospital, Zibo 255400, Shandong, P. R. China
1 shared publication - Jingjing Xu
Department of Respiratory and Critical Care Medicine, Zibo Municipal Hospital, Zibo 255400, Shandong, P. R. China
1 shared publication - Lijun Suo
Department of Respiratory and Critical Care Medicine, Zibo Municipal Hospital, Zibo 255400, Shandong, P. R. China
1 shared publication
Latest Publications
- 17 June 2025
- Published by World Scientific Pub Co Pte Ltd in Nano LIFE
PEGylated Chitosan-Albumin Nanocomposite for Efficient siRNA Delivery Against Lung Cancer
Background: The utilization of siRNA therapeutics in cancer treatment offers significant potential; however, the targeted delivery of siRNAs to tumor cells remains a major challenge. This study presents a novel folate-targeted PLGA–PEG-stabilized chitosan–albumin nanocomposite (FA-PPC-siRNA) designed for efficient siRNA delivery to cancer cells. Methods: The physicochemical properties of FA-PPC-siRNA were characterized, and its encapsulation efficiency, release profile, cellular uptake and antitumor effects were evaluated in vitro and in vivo. Results: The average particle size of FA-PPC-siRNA was (186.62[ ]±[ ]8.93) nm and the zeta potential was (23.61[ ]±[ ]3.93) mV. The encapsulation efficiency reached (96.28[ ]±[ ]4.5)%. Over a 24-h period, the cumulative siRNA release rate was (93.62[ ]±[ ]3.48)%, showing a pH-dependent release pattern. FA-PPC-siRNA demonstrated effective targeting and uptake by lung cancer cells, along with low cytotoxicity. It significantly inhibited the proliferation of lung cancer cells and exhibited excellent biocompatibility and tumor suppression in vivo. Conclusions: The FA-PPC-siRNA developed in this study exhibits lung cancer cell targeting capabilities and controlled drug release properties, facilitating efficient siRNA delivery and antitumor effects. This innovative nanocomposite shows promising potential for siRNA-based tumor-targeted drug delivery.
- 17 June 2025
- Published by World Scientific Pub Co Pte Ltd in Nano LIFE
PEGylated Chitosan-Albumin Nanocomposite for Efficient siRNA Delivery Against Lung Cancer
Background: The utilization of siRNA therapeutics in cancer treatment offers significant potential; however, the targeted delivery of siRNAs to tumor cells remains a major challenge. This study presents a novel folate-targeted PLGA–PEG-stabilized chitosan–albumin nanocomposite (FA-PPC-siRNA) designed for efficient siRNA delivery to cancer cells. Methods: The physicochemical properties of FA-PPC-siRNA were characterized, and its encapsulation efficiency, release profile, cellular uptake and antitumor effects were evaluated in vitro and in vivo. Results: The average particle size of FA-PPC-siRNA was (186.62[ ]±[ ]8.93) nm and the zeta potential was (23.61[ ]±[ ]3.93) mV. The encapsulation efficiency reached (96.28[ ]±[ ]4.5)%. Over a 24-h period, the cumulative siRNA release rate was (93.62[ ]±[ ]3.48)%, showing a pH-dependent release pattern. FA-PPC-siRNA demonstrated effective targeting and uptake by lung cancer cells, along with low cytotoxicity. It significantly inhibited the proliferation of lung cancer cells and exhibited excellent biocompatibility and tumor suppression in vivo. Conclusions: The FA-PPC-siRNA developed in this study exhibits lung cancer cell targeting capabilities and controlled drug release properties, facilitating efficient siRNA delivery and antitumor effects. This innovative nanocomposite shows promising potential for siRNA-based tumor-targeted drug delivery.